INT143643

Context Info Confidence 0.23 First Reported 2007 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 2 Total Number 2 Disease Relevance 0.96 Pain Relevance 0.19

mitochondrion (Fasn) lyase activity (Fasn) oxidoreductase activity (Fasn) Golgi apparatus (Fasn) plasma membrane (Fasn) cytoplasm (Fasn)

Anatomy Link Frequency nucleus 2 Fasn (Rattus norvegicus)

Pain Link Frequency Relevance Heat cINOD 2 97.96 cytokine 3 6.68 tolerance 5 5.00 Inflammation 2 5.00 alcohol 2 5.00 Bioavailability 2 5.00 fibrosis 1 5.00 Pain 1 5.00 Potency 1 5.00

Disease Link Frequency Relevance Heat Breast Cancer 5 99.46 INFLAMMATION 3 97.24 Body Weight 4 87.80 Metabolic Syndrome 10 87.20 Weight Gain 1 86.04 Obesity 4 74.32 Diabetes Mellitus 21 61.00 Overweight 1 43.12 Cancer 7 5.00 Stress 5 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Celecoxib decreases fatty acid synthase expression via down-regulation of c-Jun N-terminal kinase-1.

Negative_regulation (decreases) of Gene_expression (expression) of fatty acid synthase

1) Confidence 0.23 Published 2007 Journal Exp. Biol. Med. (Maywood) Section Title Doc Link 17463161 Disease Relevance 0.24 Pain Relevance 0.19

In addition, the inhibition of growth and suppression of lipogenesis in MCF-7 breast cancer cells may be through down-regulation of fatty acid synthase gene expression in the nucleus and stimulation of cell energy expenditure in the mitochondria [107,108].

Negative_regulation (regulation) of Gene_expression (expression) of fatty acid synthase gene in nucleus associated with breast cancer

2) Confidence 0.02 Published 2010 Journal Chin Med Section Body Doc Link PMC2855614 Disease Relevance 0.72 Pain Relevance 0

General Comments

This test has worked.